Please assess the completion status of the following clinical trial:

Trial Title: RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have histologically confirmed adenocarcinoma of the prostate, with biopsies obtained within 12 months of registration~  * Gleason score 3+3 or 3+4~ * PSA \<10 ng/mL within 3 months of enrollment~ * Clinical stage T1a-T2a by digital rectal exam~ * Up to 2 intraprostatic nodules visible on MRI, with combined volume \<50% of the total prostate volume~* Karnofsky Performance Status (KPS) \>70%.~* Life expectancy \>10 years~* Age ≥ 19 years~* Subjects given written informed consent~Exclusion Criteria:~* \>2 MRI defined nodules representing prostate cancer~* Total volume of MRI nodules exceeding 50% of total prostate volume~* Positive biopsy core in sextant region without MRI defined nodule (i.e. biopsy proven MRI occult prostate cancer)~* American Urological Association (AUA) urinary score ≥ 18.~* History of inflammatory bowel disease.~* Prior pelvic surgery~* Prior treatment for prostate cancer~* Patients using immunosuppressive medications or other medications that may increase radiation toxicity such as methotrexate, sirolimus, tacrolimus, or colchicine that are unable to discontinue these medications during SBRT course. Use of corticosteroids is not considered an exclusion criteria.~* Platelet count \< 70,000/µL~* Patients unable to discontinue anti-platelet or anti-coagulant medicine such as clopidogrel, dabigatran, warfarin, or low molecular weight heparin. Use of aspirin is not an exclusion criteria.~* Contraindication to MRI such as implanted devices.~* Metallic pelvic implants resulting in imaging artifact within the prostate on MRI or CT

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Focal SBRT with intra-urethral radiotransponder (Type: EXPERIMENTAL): This study will enroll patients that have a confirmed histology of prostate cancer. They will undergo a 3T MRI scan as well as a CT simulation with 16 French Foley Catheter containing dummy beacons for treatment planning purposes. The patient will then receive focal stereotactic body radiotherapy (SBRT) at a dose of 40 gy in 5 total fractions. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).